{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=26", "query": { "condition": "Gastrointestinal Cancer Metastatic", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 2359, "total_pages": 236, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:31:28.143Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02138617", "title": "Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2014-05-06", "completion_date": "2024-08-01", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 7, "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Chapel Hill, North Carolina + 4 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02138617" }, { "nct_id": "NCT07259317", "title": "Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma", "Carcinoma, Pancreatic Ductal" ], "interventions": [ { "name": "Relacorilant", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-01-27", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07259317" }, { "nct_id": "NCT04793958", "title": "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Colorectal Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "mFOLFOX6 Regimen", "type": "DRUG" }, { "name": "FOLFIRI Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2021-06-24", "completion_date": "2026-10-23", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 185, "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04793958" }, { "nct_id": "NCT07128355", "title": "Botensilimab, Balstilimab, and SBRT in Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-05-12", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128355" }, { "nct_id": "NCT05827055", "title": "Proglumide and Chemotherapy for Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Proglumide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-01-31", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05827055" }, { "nct_id": "NCT03775525", "title": "Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Gastric Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer Metastatic", "Colo-rectal Cancer", "Solid Tumor", "Solid Carcinoma", "Solid Carcinoma of Stomach", "Cancer of Stomach", "Lymphoma", "Sarcoma", "Cutaneous T Cell Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Basal Cell Carcinoma", "Cutaneous T-cell Lymphoma", "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "GZ17-6.02", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzada Pharmaceuticals USA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2019-03-01", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-12-23", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775525" }, { "nct_id": "NCT05053555", "title": "High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Malignant Tumors", "Cholangiocarcinoma Metastatic", "Pancreatic Cancer", "Melanoma" ], "interventions": [ { "name": "high dose rate brachytherapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 60, "start_date": "2022-04-24", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05053555" }, { "nct_id": "NCT04682847", "title": "Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Liver Neoplasms", "Hepatic Cirrhosis", "Hepatic Carcinoma", "Liver Cancer", "Liver Metastases", "Liver Carcinoma", "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Hepatic Atrophy" ], "interventions": [ { "name": "Ferumoxytol injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 40, "start_date": "2020-11-19", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04682847" }, { "nct_id": "NCT06731478", "title": "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 726, "start_date": "2025-02-27", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 18, "location_summary": "New Haven, Connecticut • Skokie, Illinois • Kansas City, Kansas + 15 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06731478" }, { "nct_id": "NCT00017043", "title": "BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2013-04-05", "last_synced_at": "2026-11-15T19:31:28.143Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017043" } ] }